Search | Clinical Trials Finder

Conditions: Secondary Hypogonadism
Interventions: Androxal, AndroGel, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Healthy
Interventions: LowT, Resistance Training, Placebo, HighT; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Prostate Cancer
Interventions: Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: AndroGel, placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Klinefelter Syndrome, XXY Syndrome
Interventions: Testosterone gel 1%, Placebo gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypogonadism, Male
Interventions: Testosterone Cypionate Injection 200 mg/mL; Drug
Lead sponsor: Azurity Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 3 more

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion, Spinal Cord Trauma, Trauma, Nervous System, Wounds and Injuries, Spinal Cord Compression, Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male
Interventions: testosterone cypionate, finasteride, placebo injection, placebo pill; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 4
States / cities: Aurora, Colorado • Gainesville, Florida • Tampa, Florida + 1 more

Conditions: Hypogonadism
Interventions: AndroGel 1.62%; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 45
States / cities: Foley, Alabama • Newport Beach, California • Northridge, California + 40 more

Conditions: Hypogonadism
Interventions: Testosterone, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Metabolic Syndrome
Interventions: Zoladex, Testosterone gel, Anastrozole Pill, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate; Procedure · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypogonadism, Primary Hypogonadism, Secondary Hypogonadism
Interventions: Testosterone Undecanoate 750 mg, Testosterone Undecanoate 1000 mg; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Hypogonadism, Cardiovascular Diseases
Interventions: AndroGel®, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 5,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 379
States / cities: Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more

Conditions: Prostate Cancer
Interventions: therapeutic testosterone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 66
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more

Conditions: Klinefelter Syndrome
Interventions: testosterone cypionate 200mg/ml; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 42 Days to 108 Days · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer
Interventions: GnRh (Leuprolide), Testosterone Gel, Docetaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Testosterone injection, Etoposide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Low Testosterone, Hypogonadism, Pain
Interventions: Testosterone Gel, Placebo Gel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stress Urinary Incontinence, Menopause
Interventions: Testosterone cypionate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography; Procedure · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sex Disorders
Interventions: testosterone enanthate, duastride; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

TEAM: Testosterone Supplementation and Exercise in Elderly Men

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial

A Study of the Effect of Topical Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism

Cycled Testosterone Replacement Study

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Testosterone and Pain Sensitivity

Effect of Testosterone in Men With Erectile Dysfunction

The Anabolic Effect of Testosterone on Pelvic Floor Muscles

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

The Effect of 5-Alpha Reductase on Testosterone in Men